| ASVs | Amplicon sequence variants |
| BAL | Bronchoalveolar lavage |
| CF | Cystic fibrosis |
| CFLD | Cystic fibrosis-related liver disease |
| CFRD | Cystic fibrosis-related diabetes |
| CFTR | Cystic fibrosis transmembrane conductance regulator |
| CT | Chest radiography |
| CTRLs | Controls |
| DIOS | Distal intestinal obstruction syndrome |
| EMA | European Medicines Agency |
| ETI | Elexacaftor/tezacaftor/ivacaftor |
| FDA | Food and Drug Administration |
| GI | Gastrointestinal |
| GM | Gut microbiota |
| KEGG | Kyoto Encyclopedia of Genes and Genomes |
| LCI | Lung clearance index |
| LDA | Linear discriminant analysis |
| LEfSe | Linear discriminant analysis effect size |
| MDR | Multi-drug resistant |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| NIV | Non-invasive ventilation |
| OPBG | Ospedale Pediatrico Bambino Gesù |
| PCA | Principal component analysis |
| PCoA | Principal coordinate analysis |
| PERT | Pancreatic enzyme replacement therapy |
| PICRUSt2 | Phylogenetic Investigation of Communities by Reconstruction of Unobserved States |
| pwCF | People with cystic fibrosis |
| RMSE | Root mean square error |
| SD | Standard deviation |
| SEM | Standard error of mean |